Medicus Pharma Ltd. - Common Stock (MDCX)

Dr. Raza Bokhari, Executive Chairman & CEO will participate in panel discussions and highlight Company's AI-enabled Drug Development Strategy

American Lithium Minerals Inc (OTC: AMLM ) is positioned in he global financial system is entering what many analysts describe as the next phase of asset digitization, where Real-World Asset (RWA) tokenization brings traditional commodities, infrastructure, and financial assets onto blockchain-based platforms. Industry forecasts from major financial institutions suggest that tokenized real-world assets could represent a multi-trillion-dollar market by the end of the decade , driven by demand for greater liquidity, transparency, and global accessibility in traditionally illiquid markets such as commodities and private assets.

The Company Reported 73% Clinical Clearance in the 200-µg cohort at Day 57

NEW YORK CITY, NEW YORK / ACCESS Newswire / March 7, 2026 / New to The Street, one of the longest-running U.S. business television platforms spotlighting emerging growth companies and market innovation since 2009, will broadcast Shows 736, 737 and 738 tonight on Bloomberg Television at 6:30 PM EST. The programs will air across the United States, Latin America, and the Middle East & North Africa (MENA) as sponsored programming and will also be distributed digitally through the rapidly expanding New to The Street TV YouTube platform and NewsOut distribution network, which together reach more than 5 million subscribers worldwide.

Dr. Raza Bokhari, Exec Chairman & CEO, Interviewed by Bloomberg Open Interest Anchor Matt Miller

The Company is expected to finalize the Clinical Study Report (CSR) in Q2 2026 to support planned end of Phase 2 (EOP2) meeting with the FDA

Company Exec. Chairman & CEO in a fireside chat is expected to highlight the role of Skinject in an autosomal dominant rare disease, AI-enabled drug development strategy and partnering readiness

The Show Will Also Air Across Latin America and MENA 1230 pm local time.

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2026 / New to The Street, the nationally syndicated, long-form television and digital media platform, today announced it has signed a six-part media series with Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development program of novel and potentially disruptive therapeutics assets.

The Company is developing Teverelix® as a best-in-class market product for advanced prostate cancer patients with high CV risk and a first in class product for Acute Urinary Retention Relapse prevention (AURr) collectively representing ~US$6 billion in potential market opportunity

Amendment reduces and simplifies royalty structure on Teverelix® from ~4% to 2% while preserving global rights and IP control

The Company enters 2026 with Multiple Phase 2 Catalysts, AI-enabled drug development strategy, and regulatory optionality as SKNJCT-003 study approaches database lock, topline clinical data readout and partnering readiness

The Company’s abstract, Evaluation of Teverelix in Healthy Female Volunteers, has been accepted for presentation at American Association of Clinical Endocrinology (AACE) Annual meeting 2026

The Company enters 2026 with Multiple Phase 2 Catalysts collectively representing ~$8 billion in potential market opportunities, an AI-enabled development strategy, and regulatory optionality

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute urinary retention (AURr) and high CV risk prostate cancer collectively representing ~$6 billion in potential market opportunity

THE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST END-OF-PHASE 2 (EOP2) WITH THE FOOD AND DRUG ADMINISTRATION (FDA) IN H1 2026

Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction

Skin cancer is the most common cancer in the United States, with more than five million non-melanoma cases—overwhelmingly basal cell carcinomas—diagnosed each year. Aging populations, increased sun exposure, and rising detection rates continue to drive demand for treatment. Against this backdrop, Medicus Pharma (NASDAQ: MDCX) emerges as a compelling small-cap opportunity. The company is developing SkinJect™, a patented dissolvable microneedle patch that delivers chemotherapy directly into tumors. If successful, it could offer a lower-cost, non-surgical alternative to conventional skin-cancer procedures, positioning the company within a market projected to approach six billion dollars by 2030.

Carolyn Bonner Succeeds James ('Jim') Quinlan Who Has Resigned for Health Reasons After Taking Medical Leave in September 2025

PHILADELPHIA, Nov. 24, 2025 (GLOBE NEWSWIRE) -- November is Men’s Health Awareness Month, a time to spotlight the latest medical breakthroughs that may transform how we detect and treat cancer– especially prostate and skin cancer, which are among the most common cancers affecting men. 

SKNJCT-003 Doxorubicin containing Microneedle Array (D-MNA) clinical development program to non-invasively treat BCC aligns with national priorities of public health impact, unmet medical need, access, affordability, domestic manufacturing and rare-disease alignment.

SKNJCT-003 Doxorubicin containing Microneedle Array (D-MNA) clinical development program to non-invasively treat BCC aligns with national priorities of public health impact, unmet medical need, access, affordability, domestic manufacturing and rare-disease alignment

Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing

THE SKNJCT-003 CLINICAL STUDY EXPANSION INTO THE UNITED KINGDOM TO FURTHER ENABLE GLOBAL PATIENT RECRUITMENT AND CLINICAL DATASET TOWARD A PIVOTAL STUDY PROGRAM

Skin cancer has become one of the fastest-growing cancers worldwide, with tens of millions of new cases diagnosed each year. Yet the standard treatment for basal cell carcinoma (BCC), the most common form of skin cancer, remains surgical removal. Surgery is effective but costly, can leave scars, and often must be repeated for patients who develop multiple lesions. Growing demand for noninvasive alternatives has created opportunities for companies developing targeted, patient-friendly therapies. One such innovator is Medicus Pharma Ltd. (NASDAQ: MDCX ).